๐ฐ Nasdaq Bbio News
Page 2 - Nasdaq Bbio News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Bbio. Real-time updates on events, politics, business and more.
February 7, 2024
- BridgeBio grants Kyowa Kirin exclusive license to develop and commercialize infigratinib for skeletal dysplasias in Japan - BridgeBio to receive...
February 6, 2024
Blueshift Asset Management LLC purchased a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 16,482 shares of the company’s stock, valued at approximately $435,000. Several other large investors have also recently made changes to […]
February 4, 2024
BMO Capital Markets assumed coverage on shares of BridgeBio Pharma (NASDAQ:BBIO – Free Report) in a research note published on Wednesday morning, MarketBeat reports. The firm issued a market perform rating and a $37.00 price objective on the stock. A number of other brokerages also recently issued reports on BBIO. Citigroup assumed coverage on BridgeBio […]
January 4, 2024
Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the thirteen brokerages that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating on the company. The average 1 […]
January 3, 2024
PALO ALTO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (โBridgeBioโ or the โCompanyโ), a commercial-stage...
January 2, 2024
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) and Equillium (NASDAQ:EQ – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations. Institutional & Insider Ownership 90.9% of BridgeBio Pharma shares […]
December 31, 2023
BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) has received an average rating of “Moderate Buy” from the thirteen analysts that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and twelve have given a buy recommendation to the company. The average 12 month price objective among […]
December 21, 2023
BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) Director Randal W. Scott sold 2,000 shares of BridgeBio Pharma stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $40.00, for a total value of $80,000.00. Following the completion of the transaction, the director now owns 9,000 shares of […]
December 15, 2023
BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) hit a new 52-week high during mid-day trading on Friday . The company traded as high as $37.03 and last traded at $36.34, with a volume of 530472 shares traded. The stock had previously closed at $35.91. Analyst Upgrades and Downgrades BBIO has been the topic of […]
December 10, 2023
Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have received a consensus rating of “Moderate Buy” from the thirteen analysts that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. The average […]